1,079 reports of this reaction
1.7% of all DOXORUBICIN HYDROCHLORIDE reports
#14 most reported adverse reaction
HAIR TEXTURE ABNORMAL is the #14 most commonly reported adverse reaction for DOXORUBICIN HYDROCHLORIDE, manufactured by Baxter Healthcare Company. There are 1,079 FDA adverse event reports linking DOXORUBICIN HYDROCHLORIDE to HAIR TEXTURE ABNORMAL. This represents approximately 1.7% of all 64,420 adverse event reports for this drug.
Patients taking DOXORUBICIN HYDROCHLORIDE who experience hair texture abnormal should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAIR TEXTURE ABNORMAL is a less commonly reported adverse event for DOXORUBICIN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to hair texture abnormal, the following adverse reactions have been reported for DOXORUBICIN HYDROCHLORIDE:
The following drugs have also been linked to hair texture abnormal in FDA adverse event reports:
HAIR TEXTURE ABNORMAL has been reported as an adverse event in 1,079 FDA reports for DOXORUBICIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAIR TEXTURE ABNORMAL accounts for approximately 1.7% of all adverse event reports for DOXORUBICIN HYDROCHLORIDE, making it a notable side effect.
If you experience hair texture abnormal while taking DOXORUBICIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.